I think I’ve already answered that question when I gave the statistics in terms of the 62-day performance and the 31-day performance. Sometimes, of course, clinicians tell me that it’s not that easy to start treatment within 62 days because of the nature of the cancer itself, its position in the body and, indeed, the need to look very carefully at having the most targeted treatment for the individual. If you’re an individual with cancer, of course, well, yes, you need to have certainty as quickly as possible. I understand that—the very human need. That’s why, of course, we’re seeing the improvements in the performance of ABMU in that field.